Study Overview
This report presents the latest findings from the Colo205-e396 study, conducted by Charles River Discovery Services, which evaluates the potential of SAC-SG (150 mg/kg, BID, PO for 21 days) in a preclinical colorectal cancer model.
The results are promising and represent a meaningful step forward in cancer treatment.
Executive Summary
The Colo205-e396 study, conducted by Charles River Discovery Services, demonstrated that SAC-SG (150 mg/kg, BID, PO for 21 days) significantly inhibited tumor growth by 31.4% and reversed cancer-induced weight loss by Day 15, while the weight of vehicle-administered mice showed fluctuations. It is assumed that the initial weight loss in mice administered SAC SG is due to the metabolic burden caused by the secretion of tumor cell debris destroyed by SAC SG. (A similar phenomenon is observed in TLS. And Weight loss is a symptom of tumor lysis syndrome (TLS) in Chemo therapy). SAC-SG not only halted tumor progression but also restored systemic health, making it a powerful intervention against cancer-related deterioration. With a strong safety profile and no treatment-related side effects, these findings confirm SAC-SG as a highly effective cancer treatment.

